Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00489073 · ClinicalTrials.gov registry record · Phase 3
Duloxetine Versus Placebo for Fibromyalgia
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 345
- Enrollment target
NCT00489073: Completed Phase 3 study, sponsored by Eli Lilly and Company.
NCT00489073 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 345 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00489073, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 345 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine if duloxetine reduces pain severity in patients with fibromyalgia.
Interventions
- DRUG placebo
- DRUG duloxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 345 participants |
| Start Date | 2002-11 |
| Est. Completion | 2003-12 |
| Phase | Phase 3 |
What the finished NCT00489073 record still lists
NCT00489073 is an interventional study that assigns participants to a tested intervention. The registered 345 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00489073 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00489073 about?
NCT00489073 is a clinical study titled "Duloxetine Versus Placebo for Fibromyalgia". The primary purpose of this study is to determine if duloxetine reduces pain severity in patients with fibromyalgia.
What is the current status of trial NCT00489073?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 345 participants. The study started on 2002-11. Estimated completion is 2003-12.
What interventions are being tested in trial NCT00489073?
The interventions under investigation include: placebo (DRUG), duloxetine (DRUG).
Who is sponsoring clinical trial NCT00489073?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00489073's enrollment target sits among peer trials
345 1050th of 2000 higher than 951 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03972657 · 345 participants · Phase 1
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
- NCT05107674 · 345 participants · Phase 1
A Study of NX-1607 in Adults With Advanced Malignancies
- NCT05700279 · 345 participants · NA
Preventing the Development of Chronic Pain: Treating PTSD at Acute Pain Onset
- NCT05781100 · 345 participants · NA
Investigating Baby Behavior and Family Technology Use Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia